Biogen

December 28, 2017December 21, 2017

Zinbryta Fails to Prevent RRMS from Worsening After Patient Gets Off Tysabri, Case Study Shows

News

Zinbryta (daclizumab) may not be the best follow-up therapy for relapsing–remitting multiple sclerosis patients who stop taking Tysabri (natalizumab) for safety reasons, a case study suggests. ... Read more

December 15, 2017December 15, 2017

Ocrevus’ Use Continues Rising, with RRMS Patients Receiving the Most Attention

News

U.S. neurologists are increasingly prescribing Genentech’s Ocrevus (ocrelizumab) to their multiple sclerosis patients, Spherix Global Insights reports. Another good sign for Genentech is that, in just three ... Read more

December 12, 2017December 11, 2017

Should MS Therapy Prices Reflect How Diligently We Take Our Meds?

Columns, The MS Wire - A Column by Ed Tobias

Would you be more likely to stick to your MS drug schedule if being diligent lowered the cost of that drug? Biogen, which makes half a ... Read more

December 4, 2017December 3, 2017

Bryan Bickell: 365 Days with MS and Still Fighting

Columns

Editor’s Note: Bryan Bickell, a second-round National Hockey League draft for the Chicago Blackhawks in 2004, played his last NHL game as a forward with the ... Read more

November 29, 2017November 30, 2017

Alkermes, Biogen Partnering on Therapy for Relapsing Forms of Multiple Sclerosis

Alexa, News

Alkermes and Biogen have begun working together on a compound known as ALKS 8700 as a potential treatment for relapsing forms of multiple sclerosis. Under the agreement, Alkermes will be responsible ... Read more

November 28, 2017November 30, 2017

European Neurologists Ready to Use Both Mavenclad and Ocrevus, Survey Shows

News

Mavenclad has become the multiple sclerosis therapy of choice for one in five neurologists in Germany and the United Kingdom, according to a Spherix Global Insights survey. Meanwhile, many ... Read more

November 21, 2017November 21, 2017

Patients Tell Their Stories in Consortium of Multiple Sclerosis Centers’ Online Videos

News

Maryland special education teacher Ingrid Hanson says that since she was diagnosed with multiple sclerosis five years ago, she’s developed a better understanding of her students’ ... Read more

November 8, 2017November 8, 2017

Global Phase 3 Trial of Oral Ponesimod Plus Tecfidera Enrolling Relapsing MS Patients

News

Actelion is recruiting about 600 relapsing multiple sclerosis (MS) patients to a Phase 3 trial testing the addition of oral ponesimod to Tecfidera (dimethyl fumarate) in people ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Early High-Efficacy Treatment Reduces Disability Accumulation in Young MS Patients

News

While early use of high-efficacy treatments lowers relapse rates among patients with relapsing-remitting multiple sclerosis (MS) compared to lower-efficacy ones, starting these therapies earlier may only ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Researchers Suggest Best Time to Stop Tysabri During Pregnancy

News

Babies born to women who are treated with Tysabri (natalizumab) during pregnancy are more likely to develop abnormal blood cell counts if the treatment continues beyond ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Real-world Data Leading Way to Personalized Treatment, Biogen Says in Interview

News

Personalized medicine is the future of multiple sclerosis treatment, and research now taking place to collect and analyze data and pinpoint biomarkers will help make possible ... Read more

October 25, 2017October 25, 2017

#MSParis2017 – New Trial of Opicinumab, an Anti-LINGO Antibody, in MS Builds on Lessons Learned, Biogen Says

News

Opicinumab, an investigative treatment aiming to promote remyelination in relapsing multiple sclerosis (MS) patients, will be tested in a new clinical trial —  having failed at ... Read more

October 23, 2017October 24, 2017

#MSParis2017 – Biogen to Focus on Real-world Data from Range of Efforts to Understand MS

News

In its work on multiple sclerosis (MS), Biogen has adopted a comprehensive approach that ranges from  drug development to the exploration of real-world data and digital markers ... Read more

October 18, 2017October 19, 2017

#MSParis2017 – Progressive MS Research Among ECTRIMS Highlights, National MS Society Says

News

The 7th Joint ECTRIMS-ACTRIMS Meeting, taking place in Paris this month, is one of the largest scientific conferences focused solely on multiple sclerosis (MS), and the ... Read more

October 17, 2017October 17, 2017

Biogen, Others Working with ACP to Analyze and Use MS Data to Advance Research

News

BC Platforms announced that Biogen and the Accelerated Cure Project (ACP) will use its platform to advance research in multiple sclerosis (MS) by bringing data collected through clinical ... Read more

October 16, 2017October 17, 2017

Multiple Sclerosis Therapy Aubagio May Cause Nail Loss, Researchers Report

News

Aubagio (teriflunomide) may lead to reversible nail loss, researchers at Italy’s University of Bologna reported after reviewing the case of a 55-year-old woman with relapsing-remitting multiple sclerosis. They described ... Read more

September 14, 2017September 13, 2017

There’s an App (Maybe Too Many) for That!

Columns, Engaging Thoughts

How many hours do the pharmaceutical companies think we have in our day? I ask because almost all of them have come up with very slick ... Read more

August 7, 2017August 7, 2017

MS News That Caught My Eye This Week: Resistance Training, Tysabri Report, Cognigram, and Depression

Columns, The MS Wire - A Column by Ed Tobias

Resistance Training Can Slow MS Patients’ Brain Shrinkage, Clinical Trial Indicates Over the years, studies have shown the benefits of various types of exercise in improving ... Read more

August 1, 2017August 1, 2017

Abarca, Biogen Sign Value-based Reimbursement Contract for Multiple Sclerosis Therapies

News

Abarca Health has signed a value-based reimbursement contract with Biogen for select products in its multiple sclerosis (MS) portfolio. This is the first time such an agreement ... Read more

June 30, 2017July 2, 2017

Link Between MS Therapy Tysabri and Melanoma Possible, an Adverse Reactions Watchdog Group Says

News

The multiple sclerosis therapy Tysabri could trigger melanoma, the Southern Network on Adverse Reactions (SONAR) has warned. Although its investigation failed to demonstrate that melanoma is more ... Read more

May 2, 2017May 2, 2017

Remyelination Candidate Opicinumab Failed in Phase 2 Trial in MS, But Biogen Won’t Give Up

News

Although a Phase 2b trial of the remyelination drug candidate opicinumab (also known as anti-LINGO-1 and BIIB033) failed to meet its primary goal of improving disability in ... Read more

April 25, 2017

Latest Tecfidera and Tysabri Data Suggest Treatments Improve MS Outcomes When Used Early

News

Real-world data of treatment with Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) in relapsing multiple sclerosis (MS) patients suggest that treatment at early disease stages improves outcomes ... Read more

April 20, 2017April 20, 2017

Early Use of Tecfidera and Tysabri Improves MS Patients’ Outcomes, Studies Suggest

News

The latest results on Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) use in a clinical practice setting suggest that early treatment can improve outcomes in multiple sclerosis (MS) ... Read more

March 17, 2017March 17, 2017

In Reversal, NICE Recommends Relapsing MS Treatment Zinbryta for England and Wales

News

The United Kingdom’s National Institute for Health and Care Excellence (NICE) has cleared its initial doubts and now recommends Zinbryta (daclizumab) to treat relapsing multiple sclerosis (MS) in England and ... Read more

March 3, 2017March 3, 2017

MS Organizations Join #MySupportHero Initiative to Help Patients Salute Those Who Care

News

A number of multiple sclerosis organizations have joined Biogen in the second year of the #MySupportHero initiative. The social media campaign is a way for people with multiple ... Read more

January 31, 2017January 31, 2017

Patient Opinions on Zinbryta Seen to Match Phase 3 Trial Data, Supporting Questionnaire Use

News

More relapsing multiple sclerosis (MS) patients treated with Zinbryta (daclizumab) said they felt its health benefits than did those given Avonex (interferon beta-1a) — demonstrating that patient-reported outcomes do mirror objective measures of ... Read more

January 19, 2017January 19, 2017

Siemens Healthineers and Biogen to Enhance MRI’s Ability to Help MS Patients

News

Siemens Healthineers and Biogen will collaborate to develop new magnetic resonance imaging (MRI) applications that can quantify key markers of multiple sclerosis (MS). “By bringing together the ... Read more

January 11, 2017January 12, 2017

MS PATHS: Be Aware of the Info You Share

Columns, Engaging Thoughts

Would you open your bank account and write a blank check to just anyone requesting something of value from you? Of course not. So, why would ... Read more

October 5, 2016October 12, 2016

MS Trust to Oppose NICE Plan to Reject Zinbryta as MS Therapy in Health System for England, Wales

News

The Multiple Sclerosis (MS) Trust is expressing its disappointment at the recent committee decision of the National Institute for Health and Care Excellence (NICE) to not recommend Zinbryta (daclizumab) be made available ... Read more

October 4, 2016October 12, 2016

NICE Planning to Reject MS Treatment, Zinbryta, in England and Wales

News

The National Institute for Health and Care Excellence (NICE), the health authority for England and Wales, has decided not to recommend Zinbryta (daclizumab) be made available to multiple sclerosis (MS) patients ... Read more

September 19, 2016September 19, 2016

#ECTRIMS2016 – Biogen and AbbVie Present New Positive Data on Zinbryta to Treat Relapsing MS

News

Biogen and AbbVie presented positive new post-hoc analysis from the pivotal DECIDE clinical trial, which showed that a significantly larger number of relapsing multiple sclerosis (RMS) patients treated with Zinbryta ... Read more

September 12, 2016September 12, 2016

#ECTRIMS2016 – Biogen to Unveil Study into Economic and Human Costs of MS

News

At the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, taking place in London on Sept. 14–17, Biogen will present the Multiple Sclerosis Cost of ... Read more

July 7, 2016July 7, 2016

Zinbryta (Daclizumab) Approved in Europe to Treat Relapsing MS

News

Biogen and AbbVie announced that the drug Zinbryta (daclizumab) has received marketing authorization by the European Commission, and is an approved treatment across most of Europe for adults with relapsing ... Read more

June 2, 2016June 20, 2016

MS Drug Tysabri (Natalizumab) Gets Positive Opinion from European Medicines Agency

News

Biogen, announced that TYSABRI, a drug developed to treat people with multiple sclerosis (MS) has received a positive opinion from the European Medicine Agency (EMA) recommending ... Read more

May 31, 2016May 31, 2016

Multiple Sclerosis treatment Zinbryta (Daclizumab) Approved by FDA

News

Zinbryta (daclizumab) was approved May 27 for the treatment of adults with relapsing multiple sclerosis (MS). The U.S. Food and Drug Administration (FDA) cleared Biogen’s new ... Read more

May 4, 2016May 4, 2016

CHMP Favors European Approval of Zinbryta (Daclizumab) to Treat Relapsing MS

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently recommended marketing authorization to Zinbryta (daclizumab) for the treatment of ... Read more

April 22, 2016April 22, 2016

Biogen and AbbVie Present New Data Showing Zinbryta, an RRMS Drug Candidate, Aids Cognition Without Immune Depletion

News

New data presented by Biogen and AbbVie at the recent 68th annual meeting of the American Academy of Neurology (AAN) showed that Zinbryta (daclizumab high-yield process) improved cognitive outcome measures in patients ... Read more

April 21, 2016

#HackMS Hackathon Recap

https://www.youtube.com/watch?v=ivL0F5aA2J8 In this Biogen video, watch a recap of #HackMS Hackathon, where hackers gathered at Boston’s Innovation District challenged to develop a tech-based tool to help manage daily stress ... Read more

April 20, 2016April 20, 2016

Biogen Releases New Data Showing Effectiveness of Tecfidera in Newly Diagnosed MS Patients at AAN 2016

News

Biogen reported new data describing the effectiveness of Tecfidera (dimethyl fumarate) in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients in a recent presentation at the 68th annual meeting ... Read more

April 14, 2016April 14, 2016

Array of Multiple Sclerosis Trial Data to Be Presented by Biogen at 2016 AAN Meeting

News

A range of new multiple sclerosis (MS) data from Biogen will be revealed at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada, on ... Read more